医学
高强度
安慰剂
维生素E
白质
内科学
生育三烯醇
临床试验
病理
磁共振成像
抗氧化剂
生育酚
生物化学
替代医学
化学
放射科
作者
Yogheswaran Gopalan,Ibrahim Lutfi Shuaib,Enrico Magosso,Mukhtar Alam Ansari,Mohd Rizal Abu Bakar,Jia Woei Wong,Nurzalina Abdul Karim Khan,Wei Chuen Liong,Kalyana Sundram,Bee Hong Ng,Karuthan Chinna,Kah Hay Yuen
出处
期刊:Stroke
[Lippincott Williams & Wilkins]
日期:2014-04-28
卷期号:45 (5): 1422-1428
被引量:107
标识
DOI:10.1161/strokeaha.113.004449
摘要
BACKGROUND AND PURPOSE: Previous cell-based and animal studies showed mixed tocotrienols are neuroprotective, but the effect is yet to be proven in humans. Thus, the present study aimed to evaluate the protective activity of mixed tocotrienols in humans with white matter lesions (WMLs). WMLs are regarded as manifestations of cerebral small vessel disease, reflecting varying degrees of neurodegeneration and tissue damage with potential as a surrogate end point in clinical trials. METHODS: A total of 121 volunteers aged ≥35 years with cardiovascular risk factors and MRI-confirmed WMLs were randomized to receive 200 mg mixed tocotrienols or placebo twice a day for 2 years. The WML volumes were measured from MRI images taken at baseline, 1 year, and 2 years using a validated software and were compared. Fasting blood samples were collected for full blood chemistry investigation. RESULTS: According to per-protocol (88 volunteers) and intention-to-treat (121 volunteers) analyses, the mean WML volume of the placebo group increased after 2 years, whereas that of the tocotrienol-supplemented group remained essentially unchanged. The mean WML volume change between the 2 groups was not significantly different (P=0.150) at the end of 1 year but was significant at the end of 2 years for both per-protocol and intention-to-treat analyses (P=0.019 and P=0.018). No significant difference was observed in the blood chemistry parameters between the 2 groups. CONCLUSIONS: Mixed tocotrienols were found to attenuate the progression of WMLs. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00753532.
科研通智能强力驱动
Strongly Powered by AbleSci AI